What is ramucirumab (ramucirumab)?

Ramucirumab (ramucirumab) is indicated as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have disease progression during or after prior fluoropyrimidine- or platinum-containing chemotherapy. Ramucirumab(Ramucirumab)In combination with erlotinib, it is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptors ( span>EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation. ramucirumab(ramucirumab)In combination with docetaxel, it is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities should have disease progression on an FDA-approved therapy for these abnormalities before receiving cilenza. ramucirumab(ramucirumab) and FOLFIRI ( Rinotecan, leucovorin, and fluorouracil) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after prior treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine. As a single agent, ramucirumab(ramucirumab) is indicated for the treatment of alpha-fetoprotein (AFP)≥400 ng/mLHepatocellular carcinoma (HCC) patients who have received sorafenib treatment. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0